|
1
|
Sciascia S, Mompean E, Radin M, Roccatello
D and Cuadrado MJ: Rate of adverse effects of medium- to high-dose
glucocorticoid therapy in systemic lupus erythematosus: A
systematic review of randomized control trials. Clin Drug Investig.
37:519–524. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Safy M, de Hair MJH, Jacobs JWG,
Buttgereit F, Kraan MC and van Laar JM: Efficacy and safety of
selective glucocorticoid receptor modulators in comparison to
glucocorticoids in arthritis, a systematic review. PLoS One.
12:e01888102017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rodeghiero F and Ruggeri M: ITP and
international guidelines: What do we know, what do we need? Presse
Med. 43:e61–e67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rentero ML, Amigo E, Chozas N, Fernández
Prada M, Silva-Fernández L, Abad Hernandez MA, Rodriguez Barrera JM
and del Pino-Montes J; GHDP study group, : Prevalence of fractures
in women with rheumatoid arthritis and/or systemic lupus
erythematosus on chronic glucocorticoid therapy. BMC Musculoskelet
Disord. 16:3002015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Robinson DE, Dennison EM, Cooper C, van
Staa TP and Dixon WG: A review of the methods used to define
glucocorticoid exposure and risk attribution when investigating the
risk of fracture in a rheumatoid arthritis population. Bone.
90:107–115. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rizzoli R and Biver E:
Glucocorticoid-induced osteoporosis: Who to treat with what agent?
Nat Rev Rheumatol. 11:98–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Compston J: Glucocorticoid-induced
osteoporosis: An update. Endocrine. 61:7–16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kanis JA, Johansson H, Oden A, Johnell O,
de Laet C, Melton III LJ, Tenenhouse A, Reeve J, Silman AJ, Pols
HA, et al: A meta-analysis of prior corticosteroid use and fracture
risk. J Bone Miner Res. 19:893–899. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sugiura T, Yamamoto K, Murakami K, Horita
S, Matsusue Y, Nakashima C and Kirita T: Immune thrombocytopenic
purpura detected with oral Hemorrhage: A case report. J Dent
(Shiraz). 19:159–163. 2018.PubMed/NCBI
|
|
10
|
Neunert C, Lim W, Crowther M, Cohen A,
Solberg L Jr and Crowther MA; American Society of Hematology, : The
American Society of Hematology 2011 evidence-based practice
guideline for immune thrombocytopenia. Blood. 117:4190–4207. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Provan D, Stasi R, Newland AC, Blanchette
VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB,
Godeau B, et al: International consensus report on the
investigation and management of primary immune thrombocytopenia.
Blood. 115:168–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nomura S, Kurata Y, Tomiyama Y, Takubo T,
Hasegawa M, Saigo K, Nishikawa M, Higasa S, Maeda Y and Hayashi K:
Effects of bisphosphonate administration on the bone mass in immune
thrombocytopenic purpura patients under treatment with steroids.
Clin Appl Thromb Hemost. 16:622–627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sambrook PN, Kotowicz M, Nash P, Styles
CB, Naganathan V, Henderson-Briffa KN, Eisman JA and Nicholson GC:
Prevention and treatment of glucocorticoid-induced osteoporosis: A
comparison of calcitriol, vitamin D plus calcium, and alendronate
plus calcium. J Bone Miner Res. 18:919–924. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cesareo R, Di Stasio E, Vescini F,
Campagna G, Cianni R, Pasqualini V, Romitelli F, Grimaldi F,
Manfrini S and Palermo A: Effects of alendronate and vitamin D in
patients with normocalcemic primary hyperparathyroidism. Osteoporos
Int. 26:1295–1302. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li G, Lv CA, Tian L, Jin LJ and Zhao W: A
retrospective study of alendronate for the treatment of ankylosing
spondylitis. Medicine (Baltimore). 97:e107382018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Millonig G, Graziadei IW, Eichler D,
Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A,
Margreiter R and Vogel W: Alendronate in combination with calcium
and vitamin D prevents bone loss after orthotopic liver
transplantation: A prospective single-center study. Liver Transpl.
11:960–966. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shapses SA, Kendler DL, Robson R, Hansen
KE, Sherrell RM, Field MP, Woolf E, Berd Y, Mantz AM and Santora AC
II: Effect of alendronate and vitamin D3 on fractional
calcium absorption in a double-blind, randomized,
placebo-controlled trial in postmenopausal osteoporotic women. J
Bone Miner Res. 26:1836–1844. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Siris ES, Adler R, Bilezikian J, Bolognese
M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S,
Lane NE, et al: The clinical diagnosis of osteoporosis: A position
statement from the National Bone Health Alliance Working Group.
Osteoporos Int. 25:1439–1443. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hasegawa M, Nisikawa M, Nomura S, Takubo
T, Suehiro A, Saigo K, Hayashi K, Tamaki S, Mizutani M, Uemura Y
and Kurata Y; Kinki ITP Cooperative Study Group, : Effect of
glucocorticoids on bone mineral density in patients with idiopathic
thrombocytopenic purpura. Rinsho Ketsueki. 46:121–126. 2005.(In
Japanese). PubMed/NCBI
|
|
20
|
Liao EY, Zhang ZL, Xia WB, Lin H, Cheng Q,
Wang L, Hao YQ, Chen DC, Tang H, Peng YD, et al: Calcifediol
(25-hydroxyvitamin D) improvement and calcium-phosphate metabolism
of alendronate sodium/vitamin D3 combination in Chinese
women with postmenopausal osteoporosis: A post hoc efficacy
analysis and safety reappraisal. BMC Musculoskelet Disord.
19:2102018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang L, Tian JH, He ZY, Tang XL and Yang
KH: A Meta-analysis of alendronate for the prevention and treatment
of glucocorticoid-induced osteoporosis. Zhonghua Nei Ke Za Zhi.
52:838–843. 2013.(In Chinese). PubMed/NCBI
|
|
22
|
D'Amelio P, Grimaldi A, Cristofaro MA,
Ravazzoli M, Molinatti PA, Pescarmona GP and Isaia GC: Alendronate
reduces osteoclast precursors in osteoporosis. Osteoporos Int.
21:1741–1750. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bradaschia-Correa V, Moreira MM and
Arana-Chavez VE: Reduced RANKL expression impedes osteoclast
activation and tooth eruption in alendronate-treated rats. Cell
Tissue Res. 353:79–86. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martins CA, Leyhausen G, Volk J and
Geurtsen W: Effects of alendronate on osteoclast formation and
activity in vitro. J Endod. 41:45–49. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Q, Badell IR, Schwarz EM, Boulukos
KE, Yao Z, Boyce BF and Xing L: Tumor necrosis factor prevents
alendronate-induced osteoclast apoptosis in vivo by stimulating
Bcl-xL expression through Ets-2. Arthritis Rheum. 52:2708–2718.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Siebelt M, Waarsing JH, Groen HC, Müller
C, Koelewijn SJ, de Blois E, Verhaar JA, de Jong M and Weinans H:
Inhibited osteoclastic bone resorption through alendronate
treatment in rats reduces severe osteoarthritis progression. Bone.
66:163–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Iseri K, Iyoda M, Watanabe M, Matsumoto K,
Sanada D, Inoue T, Tachibana S and Shibata T: The effects of
denosumab and alendronate on glucocorticoid-induced osteoporosis in
patients with glomerular disease: A randomized, controlled trial.
PLoS One. 13:e01938462018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boyce AM, Kelly MH, Brillante BA, Kushner
H, Wientroub S, Riminucci M, Bianco P, Robey PG and Collins MT: A
randomized, double blind, placebo-controlled trial of alendronate
treatment for fibrous dysplasia of bone. J Clin Endocrinol Metab.
99:4133–4140. 2014. View Article : Google Scholar : PubMed/NCBI
|
